Personalizing medicine for cancer: the next decade.
An important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that target the results of genetic defects in selected patients with cancer has led to some important treatment advances, but there remain major challenges to realizing the full potential of genomic medicine in oncology.